Current clinical trials
- Sonar
- Declare TIMI 58
- STRENGTH
- THEMIS: Phase 3 RCT
- CARAT
- CAMELLIA TIMI 61
- CLEAR CVOT
- HARMONY Esperion Lipid lowering trials
- PROMINENT
- ACCENTUATE
- ORION 1
- BETONMACE
- Odyssey Outcomes
- Odyssey Diabetes 1
- Odyssey Diabetes 2
Events Adjudication Committee Member
Sponsored by Abbvie
An RCT of a novel endothelin inhibitor atrasentan on CV death or end stage renal disease.
National Lead Investigator
Sponsored by AstraZeneca
Multi-centre study to test if dapagliflozin when added to a patients current anti-diabetes therapy is effective in reducing cardiovascular events such as myocardial infarction (MI) (heart attack), ischemic stroke, and cardiovascular (CV) related death, compared with placebo. Enrolment of 18,000 subjects anticipated with completion expected in 2019.
National Lead Investigator and Executive Committee Member
Sponsored by AstraZeneca
Phase 3 RCT of Omega 3 Fatty acids for the secondary Prevention of CVD.
National Lead Investigator and Steering Committee Member
Sponsored by AstraZeneca
Assessing the effect of Ticagrelor in stable CHD. Global study of 17,000 patients. Expected completion 2017
Executive Committee Member
Sponsored by Cerenis
Phase 3 RCT assessing the efficacy of a HDL mimetic on atheroma burden on IVUS.
Steering Committee Member
Sponsored by Eisai
Phase 3 trial of a novel agent for weight loss improvement of metabolic traits and CVD outcomes.
Executive Committee Member
Sponsored by Esperion
Phase 3 RCT assessing the efficacy of ETC1002 on CVD outcomes in patients at CVD risk intolerant of statins.
Executive Committee Member
Sponsored by Esperion
Phase 3 RCT assessing the efficacy of ETC1002 on LDL-C.
Steering Committee Member
Sponsored by Kowa
Phase 3 RCT assessing the efficacy of K877on CVD in people with DM and high TG low HDL-C. Commencing 2017.
Executive Committee Member
Sponsored by Lilly
Phase 3 trial of Anacetrapib on Lipid levels among those with FH or dyslipidemia intolerant of current therapies.
PI and Co-Chair of the Executive Committee
Sponsored by Medicines Company
Phase 2 RCT assessing the efficacy of a novel intervention with iRNA therapy to PCSK9 on lipids.
Chair of International Executive Committee
Sponsored by Resverlogix
Phase 3 RCT assessing the efficacy of BET inhibition on CVD.
National Lead Investigator
Sponsored by Sanofi Regeneron
Multi-centre study to compare the effect of alirocumab SAR236553 (REGN727) with placebo on the occurrence of cardiovascular events in patients who have experienced an acute coronary syndrome (ACS).
Executive Committee Member
Sponsored by Sanofi Regeneron
Phase 3 RCT assessing the efficacy of Alirocumab on lipids in patients with atherogenic dyslipidaemia and DM.
Executive Committee Member
Sponsored by Sanofi Regeneron
Phase 3 RCT assessing the efficacy of Alirocumab on lipids in patients with DM treated with insulin.